Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sorry folks...this id done for a long time...we expect low 2's by Friday
Technology is very valuable. its worth at least $500M...
Its hard to maintain high market cap with toxic dilution. These guys haven't even sold half the shares they need to finish last note.
You covered here and then got short. Good strategy. This board is like a sewer.
looks like its tanking. only 120,000,00 shares left to sell. See ya at .02
I challenge MAXM or other MMs or investors who are holding the issued shares to bring down SP at .01. If they have gutts. I know they can not. Because game is set there only. Come on guys bring it down to .01 .
I totally agree but I am not against positive surprises. I would like to see market cap stabilize over $20 million dollars, it is an essential tool among wolves
Going up from here $DCTH
Hit me with a Follow, thanks guys!
would not put much hope into buyout. Been trading for 20 years and don't even remember a single pink sheet pharma buyout of top of my head.
Company getting delisted to pinks and not being able to raise $ is a good indicator what other players think of potential. Doing toxic dilutive financing is last resort for companies. And these guys are burning through lots of $. Better hope current note sellers sell quick enough before company runs out of $ and needs to raise again.
ONFI the Short. That would be his Romanian royal title. Bwahahahahahahah
Closed? No no. Bought 10,000 yesterday and 5,555 again this morning!!!
What I meant by no horse in the race is that I don’t have much interest in thinking a single person has that much impact on PPS, except of course ONFI or whatever that joker’s name is.
Since you nailed yesterday, what's your prediction for close today?
So Rap, you closed your position? Guess I will be doing the Romania gig solo. If you should find the monkey, will you send him my way? Many thanks! hahahahahahaha
Looking ahead, which is next warrants or trying to entice lift to at least 10 cents for a financing attempt. Hopefully phase 3 talk behind the scenes can stir some interest whether buyout, partnership, or a financing deal of at least 4 cents firm
If they left the note as is it would have taken only $2.2M worth of sells to finish it. At these prices 123,000,000 shares worth $5 million. Not really a good deal for investors. But the PR that "debt" was clear was very nice touch.
I added 200Ks today, and it appears to go nowhere except up from here.
yes been churning volume at your command for months now as stock dropped $25 to .03. Only 120,000,000 more shares to go. Just slightly more than they were able to sell over last 2 months.
Now MAXM under .46
I do see your point but I always believed that shareholders were the true owners of the company. That does not seem to be the case here. The BOD is equally complicit here. We could definitely use an activist shareholder on the board but DCTH is toxic right now.
Just remove all your bids and let MAXM left hanging in the air for the next two weeks. Why support note holder's dilution? Force them out as cheap as possible. Will be back end of January. See you.
Looks like .046 is the line drawn in the sand for now!
Hence the “in theory”... just as you can’t calculate the decline of the PPS
Because the sooner you do, the faster the debt gets converted.
Or Short and help others get better prices.
You can't calculate market cap with shares that haven't been sold. If note holders are looking to convert all 123 million shares, the pps will decline accordingly. At $0.03, e.g. we are looking at a $7M fully diluted market cap with debt cleared.
Give me a good reason to buy and I will load up.
I highly doubt if anybody associated with delcath was happy settling for the convertible deal, the best way for delcath people to keep their job intact and salary level, was to do it well. It is done warts and all, but the phase 3 is an interesting study I truly want to see the end to
One more unto the breach, dear friends, once more....
Volume on target for 17M today.
123M / 17M / 2 (50% vol max) = approximately 15 trading days, minimum.
My guess is closer to 20 trading days. Puts us around the end of January.
After the note holder has sold the 123M shares at their desire, The SP will be somewhere in the .02 to .05 range.
10Q will be released that states 2017 was not a great year. (no surprise).
Then what?
Where do we go from post January?
MM
Note holders can only sell 50% the collective daily avg (currently 11.5MM) of their pro rata shares until the 15 day holding period. Not until 1/22 (the 15th trading day) can they sell above this restriction. They have access to 123MM aggregate. So yes, in theory the O/S sits at 222MM or market cap of 11MM which is higher than the 28ths closing MK by about 2MM.
Gotta give them credit though for reigning in costs during these difficult times - their Queensbury address certainly looks more humble than a suite in Manhattan! Nice lawns btw!
You are completely wrong in your thinking Sam. It is your opinion though and I respect that. Shareholders who were involved in the r/s were completely wiped out and will never get their money back. There had to be better ways to attract capital than Hudson and DCTH did not have anyone in place to seek out alternative financing. Simpson is protecting her salary and perks as long as she can hold on. That is a simple fact.
It's just short term Trading. The big thing to watch here is how different this company is from just 60 days ago. Debt gone, float has been cleaned up 350-1, REV in Europe, new Director:
Simon Pedder, Ph.D.
Director
Simon Pedder, Ph.D. Dr. Pedder joined the Delcath Board of Directors in November 2017. Dr. Pedder is a scientist and pharmaceutical executive with a 30-year career in drug development. He currently serves as Chief Business and Strategy Officer at Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. During his long career in drug development, Dr. Pedder has held several leadership positions including President and CEO of Cellectar Biosciences, President and CEO of Chelsea Therapeutics, Executive Officer and Vice President of Oncology Pharma Business at Hoffmann-LaRoche, Life Cycle Leader and Global Project Leader of Pegasys/IFN and Head of the Hepatitis Franchise at Hoffmann-LaRoche. Dr. Pedder led the late stage development and commercial launch of multiple proprietary pharmaceutical products, including Pegasys®, Copegus® and Northera®.
It will be fun to see the Shorts scramble when the next PR drops.
Pigs get fed, Hogs get slaughtered.
I still see a buyout here... time will tell.
Churn that volume baby! Get this monkey off our back.
Buyer fatigue....knowing you are at the mercy of the MM. They decide when it goes up...and when it goes down. Only a substantial PR will change that. Green market days mean nothing to the SP of this stock. You just need to buy as low as you can and hope that seller fatigue eventually settles in.
Dreamer . Not on my clock
Here we go back up!
Looks like $0.046 is holding.
Load up!
Thank you sir. This info is very helpful, truly.
Good luck today in the markets.
Truly the end that justifies the means always comes back to personally good trading, it is no fun if one does not seek self improvement
Testing $0.046 for the second time today. If support forms at $0.046, we go back up.
It’s mission to destroy this ticker like I did icld
And those screens will add to the base (as you know; saying it for others). More people who buy in, base continues to grow. Larger the base, more following the stock, more following the stock, larger the benefit to the share price when the co drops positive PRs.
Jenny did what she did to allow the company to survive. It wasn't pretty but the ends justify the means.
Followers
|
497
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
50157
|
Created
|
05/11/05
|
Type
|
Free
|
Moderators |
In December 2018, Delcath entered into a License Agreement with medac GmbH for the commercialization of the CHEMOSAT® system in Europe. Under the terms of the medac License, medac has the exclusive right to sell and market CHEMOSAT® in all member states of the EU, Norway, Liechtenstein, Switzerland, and the United Kingdom.
Since launching CHEMOSAT® in Europe, over 750 commercial treatments have been performed at over 25 European cancer centers. Physicians in Europe have used CHEMOSAT® to treat patients with a variety of cancers in the liver, primarily ocular melanoma liver metastases, and other tumor types including cutaneous melanoma, hepatocellular carcinoma, cholangiocarcinoma, and liver metastases from colorectal cancer, breast, pancreatic and neuroendocrine.Split # | Date | Ratio |
1 | April 9, 2014 | 1:16 |
2 | July 21, 2016 | 1:16 |
3 | November 6, 2017 | 1:350 |
4 | May 2, 2018 | 1:500 |
5 | December 24, 2019 | 1:700 |
Common Shares Authorized: | 1,000,000,000 |
Common Shares Outstanding: | 70,056 |
Preferred Shares Authorized: | 10,000,000 |
Preferred Shares Outstanding: | 41,447 |
Warrants: | 29 | ($42; exp 2/2020 - 10/2021) |
2019 Warrants: | 1,826,579 | ($23.04; exp 12/2024) |
Options: | 1,640 | |
Total Warrants/Options: | 1,828,248 |
Preferred Stock: | 1,799,093 |
Convertible Notes: | 63,493 |
Total Reserved: | 1,862,586 |
Jennifer K. Simpson, Ph.D. | : 2,965 |
John Purpura, M.S. | : 2,830 |
William D. Rueckert | : 2,619 |
Roger G. Stoll, Ph.D. | : 4,047 |
Marco Taglietti, M.D. | : 2,606 |
Total Shares | : 21,459 |
Altium Capital Management L.P. | : 7,204 |
Rosalind Master Fund L.P. | : 7,024 |
Hudson Bay Master Fund Ltd. | : 7,024 |
Total Shares | : 21,612 |
45 Shareholders (est.) | : 26,985 |
Company Website: Delcath Systems, Inc. | Stock and Financial Website: OTC Marketplace |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |